Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Piotroski F-Score is 5 as of Jul. 29, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,330 Biotechnology companies, Niagen Bioscience ranks better than 84.59% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Niagen Bioscience has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Niagen Bioscience's Piotroski F-Score or its related term are showing as below:
FRA:OCD1'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 8
Current: 5
During the past 13 years, the highest Piotroski F-Score of Niagen Bioscience was 8. The lowest was 2. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Niagen Bioscience Piotroski F-Score Related Terms
Niagen Bioscience Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Piotroski F-Score Comparison
For the Biotechnology subindustry, Niagen Bioscience's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Niagen Bioscience's current Net Income (TTM) was 16.0.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Niagen Bioscience's return on assets of this year was 0.21296702. Niagen Bioscience's return on assets of last year was 0.26565232.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Niagen Bioscience's gearing of this year was 0.01560861. Niagen Bioscience's gearing of last year was 0.04090004.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Niagen Bioscience's current ratio of this year was 4.60568303. Niagen Bioscience's current ratio of last year was 3.65788108.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Niagen Bioscience's number of shares in issue this year was 84.566. Niagen Bioscience's number of shares in issue last year was 83.232.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Niagen Bioscience's gross margin of this year was 0.6428189. Niagen Bioscience's gross margin of last year was 0.62498253.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Niagen Bioscience's asset turnover of this year was 1.48940016. Niagen Bioscience's asset turnover of last year was 2.01358712.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
0
+
1
+
1
+
0
+
1
+
0
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Niagen Bioscience has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Niagen Bioscience (FRA:OCD1) has a Piotroski F-Score of 5 as of Jul. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Niagen Bioscience and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Niagen Bioscience's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Niagen Bioscience ranks #205 out of 1330 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Niagen Bioscience's Piotroski F-Score too high?
Niagen Bioscience's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Niagen Bioscience's value of 5 is 66.7% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #205 out of 1330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Piotroski F-Score compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #205 out of 1330 companies for Piotroski F-Score. This places Niagen Bioscience in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Niagen Bioscience's value of 5 is 66.7% above this benchmark. Historically, Niagen Bioscience's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Niagen Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,330 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 66.7% above the Biotechnology industry median of 3.00. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Piotroski F-Score is 5 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
Industry Position: 66.7% above the Biotechnology median (#205 of 1330)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
